StockNews.com Upgrades MediWound (NASDAQ:MDWD) to Sell

MediWound (NASDAQ:MDWD) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of MediWound in a report on Thursday, May 30th.

MediWound Stock Performance

Shares of NASDAQ MDWD opened at $14.51 on Wednesday. The firm has a market cap of $134.65 million, a P/E ratio of -10.51 and a beta of 0.81. MediWound has a 1 year low of $7.10 and a 1 year high of $19.86. The firm’s 50 day moving average price is $16.58 and its 200 day moving average price is $14.73.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. The company had revenue of $4.96 million for the quarter, compared to the consensus estimate of $4.65 million. As a group, equities analysts predict that MediWound will post -1.93 EPS for the current year.

Hedge Funds Weigh In On MediWound

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDWD. Janney Montgomery Scott LLC bought a new stake in MediWound in the 1st quarter valued at $427,000. Silverberg Bernstein Capital Management LLC acquired a new stake in MediWound during the fourth quarter worth about $803,000. Sargent Investment Group LLC increased its stake in MediWound by 7.0% during the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after acquiring an additional 7,125 shares during the period. Yelin Lapidot Holdings Management Ltd. increased its stake in MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after acquiring an additional 39,348 shares during the period. Finally, Essex Investment Management Co. LLC raised its holdings in MediWound by 241.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after acquiring an additional 93,705 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.